stem-cells-istock-577639302_posteriori

posteriori / iStockphoto.com

26 February 2018Americas

Kite teams up with Sangamo to treat cancer

Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

More on this story

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

More on this story

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent